
## Patricia M Day

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2883623/publications.pdf Version: 2024-02-01



ΡΑΤΡΙCIA Μ ΠΑΥ

#	Article	IF	CITATIONS
1	Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions. Journal of Virology, 2022, 96, e0185721.	3.4	7
2	Human Papillomavirus 16 Capsids Mediate Nuclear Entry during Infection. Journal of Virology, 2019, 93,	3.4	31
3	A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells. Journal of Immunology, 2019, 202, 1250-1264.	0.8	34
4	Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism. Journal of Virology, 2017, 91, .	3.4	22
5	Efficient Production of Papillomavirus Gene Delivery Vectors in Defined InÂVitro Reactions. Molecular Therapy - Methods and Clinical Development, 2017, 5, 165-179.	4.1	11
6	A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging. Journal of Virology, 2016, 90, 1096-1107.	3.4	14
7	Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 74-89.	4.5	14
8	The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane. Virology, 2015, 481, 79-94.	2.4	11
9	Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions. PLoS ONE, 2014, 9, e101576.	2.5	22
10	Large Scale RNAi Reveals the Requirement of Nuclear Envelope Breakdown for Nuclear Import of Human Papillomaviruses. PLoS Pathogens, 2014, 10, e1004162.	4.7	135
11	Strain-Specific Properties and T Cells Regulate the Susceptibility to Papilloma Induction by Mus musculus Papillomavirus 1. PLoS Pathogens, 2014, 10, e1004314.	4.7	59
12	Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes. Vaccine, 2014, 32, 3540-3547.	3.8	39
13	Concepts of papillomavirus entry into host cells. Current Opinion in Virology, 2014, 4, 24-31.	5.4	69
14	ldentification of a Role for the <i>trans</i> -Golgi Network in Human Papillomavirus 16 Pseudovirus Infection. Journal of Virology, 2013, 87, 3862-3870.	3.4	125
15	A Human Papillomavirus (HPV) <i>In Vitro</i> Neutralization Assay That Recapitulates the <i>In Vitro</i> Process of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting Antibodies. Vaccine Journal, 2012, 19, 1075-1082.	3.1	78
16	Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. Journal of Clinical Investigation, 2012, 122, 4606-4620.	8.2	120
17	In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection. Cell Host and Microbe, 2010, 8, 260-270.	11.0	148
18	The role of furin in papillomavirus infection. Future Microbiology, 2009, 4, 1255-1262.	2.0	60

PATRICIA M DAY

#	Article	IF	CITATIONS
19	Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies. Journal of Virology, 2008, 82, 4638-4646.	3.4	149
20	Heparan Sulfate-Independent Cell Binding and Infection with Furin-Precleaved Papillomavirus Capsids. Journal of Virology, 2008, 82, 12565-12568.	3.4	133
21	Neutralization of Human Papillomavirus with Monoclonal Antibodies Reveals Different Mechanisms of Inhibition. Journal of Virology, 2007, 81, 8784-8792.	3.4	116
22	Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14252-14257.	7.1	204
23	Papillomaviruses infect cells via a clathrin-dependent pathway. Virology, 2003, 307, 1-11.	2.4	190
24	Intracellular Localization of Proteasomal Degradation of a Viral Antigen. Journal of Cell Biology, 1999, 146, 113-124.	5.2	205